The Associated Press June 9, 2010, 7:48AM ET

Human Genome Sciences says cancer drug fails study

Human Genome Sciences's potential cancer drug mapatumumab failed in a midstage study, the company said Wednesday.

There was no difference in disease response or progression-free survival rates between patients receiving the drug for multiple myeloma and the control group, the company said.

Human Genome Sciences Inc. said it expects to report full results from the study at a scientific meeting later in 2010.

Multiple myeloma is a cancer that affects bone marrow.


BW Mall - Sponsored Links

Buy a link now!